Antibody gene-based prophylaxis and therapy for biodefence

Area of Science:

• Biotechnology
• Immunology
• Biodefense

Background:

• Biowarfare (BW) and bioterrorism (BT) pose increasing threats.
• Antibodies are crucial for immune defense, neutralizing pathogens and toxins.
• Traditional passive antibody administration offers temporary protection and is costly.

Purpose of the Study:

• To explore in vivo antibody gene delivery as an alternative for biodefense.
• To develop methods for producing therapeutic antibodies against BW/BT agents.
• To investigate the potential for intracellular targeting of BW/BT agents.

Main Methods:

• In vivo delivery of genes encoding BW/BT agent-specific antibodies.
• Engineering antibody fragments for intracellular expression.
• Animal studies to assess antibody expression and therapeutic levels.

Main Results:

• Antibodies were detected as early as day 3 post-administration.
• Peak antibody levels were reached by day 7.
• Therapeutic antibody levels were maintained for over seven months after a single gene delivery.
• Intracellularly expressed antibody fragments showed potential against intracellular threats.

Conclusions:

• In vivo antibody gene delivery is a potential new strategy for prophylaxis and therapy against BW/BT agent-mediated diseases.
• This approach may offer long-lasting immunity, unlike traditional passive antibody administration.
• Further research is needed to overcome challenges before human application.